Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03274440 · ClinicalTrials.gov registry record · Phase 1
Effects of Marijuana on Symptoms of OCD
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03274440 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 14 participants.
The verdict
NCT03274440, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Neither compound is currently FDA-approved for treating OCD.
Interventions
- OTHER Placebo
- DRUG Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2020-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03274440
The ClinicalTrials.gov registry entry for NCT03274440 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03274440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03274440 about?
NCT03274440 is a clinical study titled "Effects of Marijuana on Symptoms of OCD". The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different canna...
What is the current status of trial NCT03274440?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2017-10-01. Estimated completion is 2020-10-29.
What interventions are being tested in trial NCT03274440?
The interventions under investigation include: Placebo (OTHER), Cannabis (DRUG).
Who is sponsoring clinical trial NCT03274440?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.